Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

Completed · Phase 2

Conditions studied: Carcinoma, Renal Cell, Prostatic Neoplasms

In brief

The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable disease on prior Fujisawa sponsored FK228 clinical trials.

Key facts

Study ID

NCT00106301

Run by

Celgene

People needed

2

Starts

2004-04-01

Expected to finish

2006-09-01

Last updated by the study team

2019-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient has completed 6 cycles of therapy in a prior Fujisawa-sponsored FK228 clinical trial;
• Patient has immediate past participation (not to exceed 21 days from Day 15 of cycle 6 in the previous study) in a prior Fujisawa-sponsored FK228 clinical trial;
• Patient has demonstrated stable disease, partial response or complete response as best overall response in their prior Fujisawa-sponsored FK228 clinical trial.

You may not qualify if…

• Patient has been on a prior Fujisawa-sponsored FK228 clinical trial, left the trial and then received alternative anti-neoplastic therapy

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• University of Florida — Gainesville, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• Royal Marsden Hospital — Sutton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.